New drug shows promise in slowing lung scarring
NCT ID NCT03865927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called GKT137831 in 58 people with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. The drug aims to reduce lung damage caused by harmful molecules called reactive oxygen species. Researchers measured changes in blood markers of oxidative stress and collagen breakdown to see if the drug could slow disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Temple University Medical Center
Philadelphia, Pennsylvania, 19140, United States
-
Tulane University Medical Center
New Orleans, Louisiana, 70112, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Michigan Medical Center
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care